RIO DE JANEIRO, BRAZIL - The institute's unofficial claim is that Brazil's health regulatory agency ANVISA is deferring approval, constantly requesting new data, and that meetings with the agency to reach an agreement on the documentation required for the authorization of the vaccine in the 3 to 17 year old public have been unproductive.
In light of this, the institute intends to abandon its strategy of prior discussions until a new formal request is submitted, which is still pending. The Butantan officially stated, through its press office, that this Friday's meeting was cancelled "due to scheduling issues of . . .